Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG Vaccine in Radiologically Isolated Syndrome (RIS)
2024-518901-16-00Phase 2Authorised
- Sponsor
- Fondazione Italiana Sclerosi Multipla
- Start
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of bcg vaccine in radiologically isolated syndrome (RIS), sponsored by Fondazione Italiana Sclerosi Multipla. Primary endpoint: Cumulative number of CUAL on MRI over 1 year. Planned start Nov 2024; status: authorised.
02
Drugs
bcg vaccine
03
Conditions
radiologically isolated syndrome (RIS)
Beyond the preview
Go deeper on 2024-518901-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518901-16-00.